Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma

Oncologist

Volumn 22, Issue 7, 2017, Pages 823-833

  Daud, Adil ^a   Tsai, Katy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BRAF; Drug related side effects and adverse reactions; Melanoma; Mitogen activated protein kinase signaling system; Protein kinase inhibitors

Indexed keywords

ALANINE AMINOTRANSFERASE; ANALGESIC AGENT; ANTIHISTAMINIC AGENT; ASPARTATE AMINOTRANSFERASE; B RAF KINASE INHIBITOR; BINIMETINIB; COBIMETINIB; CORTICOSTEROID; CREATINE KINASE; DABRAFENIB; EMOLLIENT AGENT; ENCORAFENIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; MYDRIATIC AGENT; PARACETAMOL; STEROID; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; AZETIDINE DERIVATIVE; B RAF KINASE; BENZIMIDAZOLE DERIVATIVE; BRAF PROTEIN, HUMAN; CARBAMIC ACID DERIVATIVE; GDC-0973; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; OXIME; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; SULFONAMIDE;

ALOPECIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLISTER; CARDIOMYOPATHY; CARDIOTOXICITY; CHILL; CHORIORETINOPATHY; CONSTIPATION; COUGHING; DECREASED APPETITE; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG TOLERABILITY; DRY SKIN; EYE TOXICITY; FATIGUE; FEVER; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HAND FOOT SYNDROME; HEADACHE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERGLYCEMIA; HYPERKERATOSIS; HYPERTENSION; HYPOTENSION; IMMUNOTHERAPY; INTERSTITIAL LUNG DISEASE; LIVER TOXICITY; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MYALGIA; NAUSEA; NON MELANOMA SKIN CANCER; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; QUALITY OF LIFE; RASH; RETINA DETACHMENT; RETINA VEIN OCCLUSION; RHABDOMYOLYSIS; SKIN PAPILLOMA; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; UVEITIS; VENOUS THROMBOEMBOLISM; VOMITING; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; GENETICS; MELANOMA; PATHOLOGY; SKIN DISEASE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZETIDINES; BENZIMIDAZOLES; CARBAMATES; FEVER; HUMANS; IMIDAZOLES; INDOLES; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; OXIMES; PIPERIDINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SKIN DISEASES; SULFONAMIDES;

EID: 85024112725     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0456     Document Type: Article

References (62)

1. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-954.
2. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-2147.
3. Long GV, Weber JS, Infante JR et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol 2016; 34:871-878.
4. Long GV, Stroyakovskiy D, Gogas H et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015;386:444-451.
5. Robert C, Karaszewska B, Schachter J et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372:30-39.
6. Ascierto PA, McArthur GA, Dreno B et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): Updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016;17:1248-1260.
7. Dummer R, Ascierto PA, Gogas HJ et al. Results of COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in BRAF-mutant melanoma. Paper presented at: 13th International Congress of the Society for Melanoma Research; November 6-9, 2016; Boston, MA.
8. Tafinlar (dabrafenib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015.
9. Mekinist (trametinib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015.
10. Zelboraf (vemurafenib) [package insert]. South San Francisco, CA: Genentech USA, Inc; 2015.
11. Cotellic (cobimetinib) [package insert]. South San Francisco, CA: Genentech USA, Inc; 2015.
12. Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutatedmetastatic melanoma:Amulticentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-365.
13. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364: 2507-2516.
14. Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl JMed 2012;367:107-114.
15. Daud A, Weber J, Sosman J et al. Updated overall survival for BRF113220: A phase 1-2 study of dabrafenib alone vs combined dabrafenib and trametinib in patients with BRAF V600 mutation-positive metastatic melanoma. J Clin Oncol 2015;33: 9036a.
16. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl JMed 2012;367:1694-1703.
17. Long GV, Stroyakovskiy D, Gogas H et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014;371: 1877-1888.
18. Flaherty K, Davies MA, Grob J et al. Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D)1trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/ K-mutant cutaneous melanoma. J Clin Oncol 2016; 34:9502a.
19. Robert C, Karaszewska B, Schachter J et al. Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Eur J Cancer 2015;51(suppl 3):3301a.
20. Larkin J, Ascierto PA, Dréno B et al. Combined vemurafenib and cobimetinib in BRAF-mutatedmelanoma. N Engl J Med 2014;371:1867-1876.
21. Grob JJ, Flaherty K, Long GV et al. Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D1T) registration trials. J Clin Oncol 2016;34:9534a.
22. Dréno B, Ascierto PA, McArthur GA et al. Adverse event (AE) incidence rates with cobimetinib (C) plus vemurafenib (V) treatment: Extended follow-up (f/u) of the phase III coBRIM study. J Clin Oncol 2016;34:9533a.
23. Robert C, Karaszewska B, Schachter J et al. Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Paper presented at: 18th Annual European Cancer Congress (ECCO) and European Society of Medical Oncology 2015 Annual Meeting; September 25-29, 2015; Vienna, Austria.
24. Lee le M, Feun L, Tan Y. A case of intracranial hemorrhage caused by combined dabrafenib and trametinib therapy for metastatic melanoma. Am J Case Rep 2014;15:441-443.
25. Flaherty DC, Hoffner BW, Lau BJ et al. Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy inmetastaticmelanoma. J Surg Oncol 2015;112:844-845.
26. McArthur GA, Chapman PB, Robert C et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, openlabel study. Lancet Oncol 2014;15:323-332.
27. Chan A, Cameron MC, Garden B et al. A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. Support Care Cancer 2015;23:2231-2244.
28. Livingstone E, Zimmer L, Vaubel J et al. BRAF, MEK and KIT inhibitors for melanoma: Adverse events and their management. Chin Clin Oncol 2014;3:29.
29. Carlos G, Anforth R, Clements A et al. Cutaneous toxic effects of BRAF inhibitors alone and in combination withMEK inhibitors for metastatic melanoma. JAMA Dermatol 2015;151:1103-1109.
30. Holderfield M, Deuker MM, McCormick F et al. Targeting RAF kinases for cancer therapy: BRAFmutated melanoma and beyond. Nat Rev Cancer 2014;14:455-467.
31. Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther AdvMed Oncol 2015;7:122-136.
32. Sanlorenzo M, Choudhry A, Vujic I et al. Comparative profile of cutaneous adverse events: BRAF/ MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol 2014;71:1102-1109.e1.
33. Gibney GT, Messina JL, Fedorenko IV et al. Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol 2013;10: 390-399.
34. Amaravadi RK, Hamilton KE, Ma X et al. Multiple gastrointestinal polyps in patients treated with BRAF inhibitors. Clin Cancer Res 2015;21:5215-5221.
35. van der Noll R, Leijen S, Neuteboom GH et al. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treat Rev 2013;39:664-672.
36. Schoenberger SD, Kim SJ. Bilateral multifocal central serous-like chorioretinopathy due to MEK inhibition for metastatic cutaneous melanoma. Case Rep OphthalmolMed 2013;2013:673796.
37. Urner-Bloch U, Urner M, Stieger P et al. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann Oncol 2014;25:1437-1441.
38. Yang AH, Huang W. Retinal vein occlusion induced by a MEK inhibitor—Impact of oxidative stress on the blood-retinal barrier. In: Lushchak VI, Gospodaryov DV, eds. Biochemistry, Genetics and Molecular Biology: Oxidative Stress and Diseases. Rijeka, Croatia: InTech Open, 2013.
39. McCannel TA, Chmielowski B, Finn RS et al. Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. JAMA Ophthalmol 2014;132: 1005-1009.
40. Joshi L, Karydis A, Gemenetzi M et al. Uveitis as a result of MAP kinase pathway inhibition. Case Rep Ophthalmol 2013;4:279-282.
41. Draganova D, Kerger J, Caspers L et al. Severe bilateral panuveitis during melanoma treatment by dabrafenib and trametinib. J Ophthalmic Inflamm Infect 2015;5:17.
42. Ribas A, Gonzalez R, Pavlick A et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: A phase 1b study. Lancet Oncol 2014;15:954-965.
43. Lee CI, Menzies AM, Haydu LE et al. Features andmanagement of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. Melanoma Res 2014;24:468-474.
44. Menzies AM, Ashworth MT, Swann S et al. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Ann Oncol 2015;26:415-421.
45. NCCN Clinical Practice Guidelines in Oncology: Melanoma. V3.2016. Available at https://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf. Accessed August 9, 2016.
46. Lacouture ME, Duvic M, Hauschild A et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. The Oncologist 2013;18: 314-322.
47. Sinha R, Edmonds K, Newton-Bishop JA et al. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: Practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 2012;167:987-994.
48. Boudon SM, Plappert-Helbig U, Odermatt A et al. Characterization of vemurafenib phototoxicity in amouse model.Toxicol Sci 2014;137:259-267.
49. Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl JMed 2012;366:480-481.
50. US National Institutes of Health. Evaluation of photosensitivity in dabrafenib or vemurafenib treated metastaticmelanoma patients—A phase IIa/ IIb study. Available at https://clinicaltrials.gov/show/NCT02052193. Accessed July 7, 2016.
51. Huang W, Yang AH, Matsumoto D et al. PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. J Ocul Pharmacol Ther 2009;25:519-530.
52. Wolf SE, Meenken C, Moll AC et al. Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma. BMC Cancer 2013;13: 561.
53. Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 2010;106:21-34.
54. Wang D, Boerner SA, Winkler JD et al. Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 2007;1773:1248-1255.
55. Mallarkey G, Mangoni AA. Targeting precision medicine toxicity: Recent developments. Ther Adv Drug Saf 2015;6:4-14.
56. Tolk H, Satzger I, Mohr P et al. Complete remission of metastatic melanoma upon BRAF inhibitor treatment—What happens after discontinuation? Melanoma Res 2015;25:362-366.
57. Carlino MS, Vanella V, Girgis C et al. Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: A case series. Br J Cancer 2016;115:1280-1284.
58. Das Thakur M, Stuart DD. The evolution of melanoma resistance reveals therapeutic opportunities. Cancer Res 2013;73:6106-6110.
59. Moriceau G, Hugo W, Hong A et al. Tunablecombinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 2015;27: 240-256.
60. Hu-Lieskovan S, Robert L, Homet Moreno B et al. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: Promise and challenges. J Clin Oncol 2014;32:2248-2254.
61. Hauschild A, Grob J, Demidov L et al. An update on overall survival (OS) and follow-on therapies in BREAK-3, a phase iii, randomized trial: Dabrafenib (D) vs. dacarbazine (DTIC) in patients (pts) with BRAF V600E mutation-positive metastatic melanoma (MM). Ann Oncol 2014;25:4374a.
62. Hauschild A, Grob J, Demidov L et al. An update on overall survival (OS) and follow-on therapies in BREAK-3, a phase iii, randomized trial: Dabrafenib (D) vs. dacarbazine (DTIC) in patients (pts) with BRAF V600E mutation-positive metastatic melanoma (MM). Poster presented at: European Society of Medical Oncology (ESMO) 2014 Annual Meeting; September 26-30, 2014; Madrid, Spain.